Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

GSK again pulls application for leucovorin, touted by FDA as potential autism treatment

 April 10, 2026

BioSpace

GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to…

RegulatoryNeuroscienceRead full story

Post navigation

Roche places a $1bn bet on C4T degrader-antibody conjugates →
← Senju launches first-in-class dry eye disease drug in Japan

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com